Background: Hematologic disorders, including myelodysplastic syndrome (MDS),
peripheral blood smears from MDS patients. 3 Given that these abnormal peripheral blood cells may be derived from abnormal bone marrow cells in MDS patients, morphological abnormalities of the cellular components of the peripheral blood may provide clues for diagnosing MDS.
Rocco et al studied peripheral blood cell abnormalities using automated hematology analyzers, and concluded that flag "dysplasia"
detected by this method was sufficiently specific and sensitive to act as a screening test for MDS 4 and thus proposed using automated hematology analyzers as a screening tool for MDS. 4 However, Koenders et al subsequently reevaluated the specificity and sensitivity of the flag dysplasia detected by automated analysis for screening of MDS 5 and reported that the sensitivity was significantly lower than that reported by Rocco et al, but the specificity for MDS screening were comparable. 5 Other studies have also demonstrated the usefulness of automated hematology analyzers as screening tools for discriminating between MDS patients and normal controls and/or patients with other hematologic disorders. 6, 7 Most previous studies, however, have investigated abnormalities of erythroid, myeloid, and/ or lymphoid cells in the peripheral blood, and none have considered platelet abnormalities. Parameters other than morphological abnormalities may offer more objective indicators.
Hematology analyzers can measure various parameters, among which several platelet parameters are good candidate indicators for MDS. 8, 9 However, to the best of our knowledge, no practical studies have investigated the value of platelet parameters in peripheral blood of MDS patients obtained using automated hematology analyzers, as screening tools.
In the current study, we investigated the platelet parameters obtained using an automated hematologic analyzer (ADVIA 2120i).
The ADVIA 2120i can measure the mean platelet volume (MPV), which shows the average size of platelets, and the mean platelet component (MPC) concentration, which shows the intrathrombocytic protein concentration. 9 Mean platelet component is an original parameter of the ADVIA, indicating loss of granules and contents in the platelet. We show that these parameters reflect the morphological characteristics of platelets in the peripheral blood of MDS patients and are useful and convenient screening markers for MDS. We also report on the appropriate analyzer settings for the screening diagnosis of MDS.
| MATERIALS AND METHODS

| Subjects
In this study, all samples for platelet research were handled as recommended by Harrison and Goodall throughout all procedures, from blood collection to operation of the hematology analyzers. 10 In brief, all specimens were measured within 2 hours after blood sampling. All of the samples analyzed in this study came from patients with no past histories of any treatment such as platelet transfusions or chemotherapies for at least 3 weeks before diagnosis and were collected at the initial visits of the patients to our hospital. were also recognized as similar diseases.
Peripheral blood samples from patients with aplastic anemia (AA) (n = 20), idiopathic thrombocytopenic purpura (ITP) (n = 25), and myeloproliferative neoplasms (MPN) (n = 35), which also show morphological or numerical platelet abnormalities, 2 were also analyzed ( Table 1) .
Myeloproliferative neoplasms was classified as follows: essential thrombocythemia (ET) (n = 20), primary myelofibrosis (n = 10), and polycythemia vera (n = 5).
| Measurements of platelet parameters and observations of morphologic characteristics
Peripheral blood samples were analyzed and platelet parameters were obtained using an ADVIA 2120i Hematology System (Siemens Healthcare Diagnostics, Tarrytown, New York).
We using an all-in-one fluorescence microscope (BZX-700; Keyence, Osaka, Japan) and its associated software, according to the manufacturer's instructions. We classified the platelets into 6 patterns according to size (normal, <4 μm; large, 4-8 μm; and giant, >8 μm) and staining of the platelet azurophil granules (normal or degranulation) ( Figure 1A ).
| MPC and MPV values in patients and controls
Reference values were calculated based on the mean ± 2 standard deviations of control values. We compared MPC and MPV values at initial diagnosis between patients with MDS, AA, ITP, MPN, and the reference values.
| Ethics
Informed consent was obtained from all patients in this study. The study protocol was approved by Osaka Medical College Hospital Ethics Committee and adhered to the Declaration of Helsinki.
| Statistical analysis
Data were analyzed using JMP12 software (SAS Institute Inc, Cary, North Carolina), receiver operating characteristic curve (ROC) analysis, and partition analysis, as described previously.
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Partition analysis is a nonparametric multivariate analysis based on the decision tree method, using a cutoff value. A classification tree is constructed with decision rules for assigning samples to categories based on a series of consecutive decisions in partition analysis. Samples were then assigned to the MDS or normal group depending on whether value of an individual predictor was greater or less than the selected cutoff value.
We set the appropriate cutoff values for MDS diagnosis by ROC analysis using MPV and MPC alone and combined. We also performed recursive partitioning analysis to diagnose MDS based on MPV and MPC. The sensitivity, specificity, and positive-and negative-predictive
values were calculated for all tested cutoff values.
Significant differences (P < .05) in MPV and MPC between MDS patients and controls were detected using the 2-tailed Mann-Whitney U test.
3 | RESULTS
| Platelet parameters and morphologic characteristics
Several giant platelets were present in the peripheral blood of MDS patients with MDS-EB2 ( Figure 1B ) but none in the peripheral blood of healthy controls. May-Grünwald Giemsa staining of smears of peripheral blood from MDS patients with high MPV and low MPC values showed numerous giant (>8 μm) platelets with decreased azurophil granules under light microscopy ( Figure 1A ). The numbers of giant and degranulated platelets varied according to the subtype of MDS: Therapy-related MDS, MDS-EB1, and MDS-EB2 were associated with more giant and degranulated platelets in the peripheral blood than other subtypes ( Figure 1B ).
| MPC and MPV in patients and controls
Platelet parameters in the controls and in patients with various diseases are shown in Table 1 
| Cutoff value based on combination of MPV and MPC for diagnosis of MDS
We determined the specific cutoff value based on a combination of Similarly, cutoff values of <25.3 g/dL for MPC and >10.0 fL for MPV determined by recursive partitioning analysis, gave sensitivity, specificity, and positive-and negative-predictive values of 78.9%, 99.9%, 97.8%, and 99.1%, respectively (Table S1) .
We, therefore, adopted the cutoff values of MPC < 25.3 g/dL and MPV > 10.0 fL as the most specific cutoff values, with the emphasis on specificity as the most important factor. When this cutoff value (<25.3 g/dL for MPC and >10.0 fL for MPV) was used, 21% of MDS (12 of 57) were not judged to be MDS (MDS-SLD, n = 3; MDS-MLD, n = 1; MDS-EB1, n = 2; MDS-2, n = 2; MDS-U, n = 2; 5q-syndrome, n = 2).
The mean MPC and MPV in ITP patients were 26.6 g/dL and 9.7 fL, respectively, and no ITP cases (0%) were judged to be MDS using these cutoff values. The mean MPC and MPV in the 20 AA cases were 24.4 g/dL and 8.9 fL, respectively, and 10% of AA cases (2 of 20) were judged as MDS using these cutoff values. The MPC and MPV among the 35 patients with MPN were 24.5 g/dL and 9.0 fL, respectively, and one MPN case (3%), who had primary myelofibrosis, was judged as MDS using these cutoff values ( Figure 2B ).
| DISCUSSION
Myelodysplastic syndrome is characterized by ineffective erythropoiesis caused by abnormalities in hematopoietic stem cells. Platelets become activated when they are collected in EDTA blood-collecting vessels, with cell surface expression of the plateletactivation marker CD62P, while MPV and MPC also change over time. 12, 13 Harrison et al thus suggested that appropriate sampling conditions were necessary for experiments involving MPV. 10 We, therefore, conducted a preliminary experiment to examine the time course of changes in platelet parameters to determine the appropriate sample conditions and confirmed that MPC decreased and MPV increased over time, as described before. 12, 13 We concluded that all procedures, including measurements using the ADVIA 2120i analyzer, should be performed within 2 hours after blood collection based on the results of confirmative experiments (data not shown).
Mean platelet volume reflects the size of the platelets, and high 15 Refractory cytopenia of childhood is not usually accompanied by peripheral blood cell dysplasia, and it was, therefore, difficult to judge RCC as MDS. Although it is not surprising that these cases were not judged as MDS with these cutoff values, the reason for the absence of giant platelets in these MDS cases is unknown. In contrast, only 2 of the 1305 controls were judged as MDS using these cutoff values, but their details were also unknown.
We also investigated the MPC and MPV in patients with ITP, MPN, and AA using the determined cutoff values. Giant platelets have been reported to occur in the peripheral blood of patients with ITP;
however, platelet production is enhanced in these patients, and granular abnormalities do not usually occur. 14 These conditions may contribute to the apparently normal MPC values in patients with ITP, thus allowing discrimination between ITP and MDS cases.
Only one of 20 patients with ET had an MPV value >10.0 fL. We speculated that, even if a few giant platelets occurred in the peripheral blood of ET patients, the MPV value provided a population average value and would, therefore, not be elevated because of the large number of normal-sized platelets.
Two of 20 cases of AA were judged as MDS using the combined cutoff values, though the details of these cases are unknown. Furthermore, a standard procedure that emphasizes time management is required to account for the fact that MPV and MPC values change with time after blood collection.
| LIMITATIONS OF THE STUDY
This study had some limitations. First, the sample size was relatively small, and further studies at other institutions are needed. Second, we focused on MDS, and confirmation of the results will be required for other blood or drug-induced hematological disorders. Third, although MPC can reflect the platelet staining very well, MPC does not directly correlate with components of platelets since MPC is measured based on the scattering light method.
| CONCLUSION
The results of the current study demonstrated that MPC and MPV values obtained using an automated hematology analyzers may be useful and convenient indicators for MDS diagnosis, particularly in
